Loading...
•
Sep 30, 2021
Scynexis Q3 2021 Earnings Report
Reported financial results for the third quarter and provided a corporate update.
Key Takeaways
SCYNEXIS reported BREXAFEMME net sales of $0.5 million since August. The company's cash balance was $100 million at the end of September, providing a cash runway into 2023. A Phase 1 trial of IV ibrexafungerp was completed.
BREXAFEMME® net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial Q3.
BREXAFEMME is now covered by commercial insurance plans representing more than 30% of commercially insured lives, exceeding internal expectations.
Intravenous (IV) ibrexafungerp is ready to advance to the next stage of clinical development following successful Phase 1 trial evaluating safety and tolerability of liposomal IV formulation in healthy patients.
Based on a $100 million cash balance at September 30 and operating plan, SCYNEXIS has a projected cash runway into 2023.
Forward Guidance
SCYNEXIS anticipates several milestones, including reporting top-line data from the Phase 3 CANDLE study by early Q2 of next year and potential approval in late 2022.
Positive Outlook
- New IV formulation of ibrexafungerp will enable the company to further expand the potential range of indications for ibrexafungerp in the hospital setting.
- Phase 3 CANDLE study last-patient/last-visit by the end of 2021 with top-line results by early Q2 2022.
- Supplemental NDA submission is anticipated in Q2 2022.
- Potential approval in late 2022.
- Enrollment in the Phase 2 SCYNERGIA study is expected to accelerate over the next two quarters.
Challenges Ahead
- BREXAFEMME may not be accepted by physicians and patients at the rate SCYNEXIS expects.
- Risks inherent in SCYNEXIS' ability to successfully develop and obtain FDA approval for ibrexafungerp for additional indications, including the IV formulation of ibrexafungerp currently in Phase 1.
- Unexpected delays may occur in the timing of acceptance by the FDA of an NDA submission.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...